Stockreport

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China [Yahoo! Finance]

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination with paclitaxel for the treatment of s [Read more]